Pancreatic Cancer Research

ResearcherXinxiang UniversityActive in the last 2 years

Cheng Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9576-5361; OpenAlex author ID A5101773792. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
3
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers

Papers 4

  1. Metabolome-Wide Mendelian Randomization Identifies Valine as a Potential Mediator of the Effect of Obesity on Pancreatic Cancer Risk. Last author DOI 10.1096/fj.202501757r↗
  2. Correction: System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. Co-author DOI 10.1186/s12967-025-07200-z↗
  3. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. Co-author DOI 10.1186/s12967-022-03632-z↗
  4. A new prognostic model for pancreatic cancer based on pyroptosis-related genes Last author DOI 10.1101/2021.11.08.467376↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liukai Ma · 3 shared papers, 2021–2025 · strength 0.72
  2. Feng Li · 2 shared papers, 2022–2025 · strength 0.53
  3. Kui Li · 1 shared paper, 2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.